Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Considers National Registry For Silicone Breast Implants

This article was originally published in The Gray Sheet

Executive Summary

Due to lower-than-expected follow-up rates for Allergan and Johnson & Johnson/Mentor’s silicone-gel-filled breast implant post-approval studies, FDA advisory panel members last week called for a national registry to better document long-term outcomes and complications.
Advertisement

Related Content

Breast Implant Makers Can Use Registries To Fulfill Post-Market Surveillance Duties
Ideal Implant Aims For Saline Breast Implant With Natural-Tissue Feel
Ideal Implant Aims For Saline Breast Implant With Natural-Tissue Feel
Post-Market Safety Data On Silicone-Gel Breast Implants May Prompt Labeling Changes
Post-Market Safety Data On Silicone-Gel Breast Implants May Prompt Labeling Changes
FDA Launches Effort To Integrate Ortho Device Registries
FDA Announces Possible Link Between Breast Implants And Cancer

Topics

Advertisement
UsernamePublicRestriction

Register

MT030495

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel